BACKGROUND: This study evaluated the efficacy and safety of the novel AspireAssist   Aspiration Therapy System for treatment of @entity28 , and its effect on @entity1 's quality of life. METHODS: A prospective observational study with 25 @entity28 subjects, mean age 48  years (range 33-65), was performed. A @entity5274 (A-tube, Aspire Bariatrics) was percutaneously inserted during a gastroscopy performed under conscious sedation. Drainage and irrigation of the stomach were performed 3 times daily, 20  min after each meal, for 1-2 years. Efficient aspiration required thorough chewing of ingested food. Treatment included a cognitive behavioral @entity353 program. RESULTS: Mean body mass index (BMI) at inclusion was 39.8  kg/m(2) (range 35-49). After 1 year mean (SD) BMI was 32.1  kg/m(2) (5.4), p   <   0.01, and excess @entity353 was 54.4% (28.8), p   <   0.01. Quality of life, as measured with EQ-5D, improved from 0.73 (0.27) to 0.88 (0.13), p   <   0.01. After 2 years BMI was 31.0  kg/m(2) (5.1), p   <   0.01, and excess @entity353 was 61.5% (28.5), p   <   0.01. There were no serious adverse events or electrolyte disorders. Compliance was 80% after 1 year and 60% after 2 years. CONCLUSIONS: Aspiration therapy is an efficient and safe treatment for @entity28 , and weight reduction improves quality of life. Excess weight was approximately halved in a year, with weight stability if treatment was continued. TRIAL REGISTRATION: Trial Register ISRCTN 49958132. Retrospectively registered 28/02/2014.

Aspiration therapy for XXXX ; a safe and effective treatment.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity5274 :: ('MESH:D005184', 'Disease') :: ['custom gastrostomy tube'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']
@entity28 :: (MESH:D009765,Disease) :: ['obesity']
